Avid Bioservices Inc (CDMO)

[RRdog]

FTM (Good to have you back),

In answer to your question about my model for MOS:

In the 12 trials you list for Phase III studies in 1st Line NSCLC I notice there are over 3,700 patients involved with a mean MOS of 9.8 months. This means the SOC is very thoroughly defined. Though PPHM MOS will be measured against MOS in the control group of its own trial, I would be surprised to see that vary much against such a large data base.

Against this 9.8 months MOS my numbers as of today put PPHM at 16 months MOS with a range of 14-19 months giving you over 95% probability.

If PPHM 1st line MOS runs out to the end of Jan 2013 that would give PPHM approx 19 month MOS with a range of 17-22 months.

The low end of both these end points is 14-17 months MOS or approximately 40-70% improvement over SOC. IMO this is signifigant in many ways.

Best Regards,
IMHO only (but my opinion is well informed)
RRdog